Module

From Bench to Bedside: The Clinical Role of Integrase Inhibitors

Source: The Role of Integrase Inhibitors in HIV Management

From Bench to Bedside: The Clinical Role of Integrase Inhibitors

Faculty:
David A. Cooper, MD, DSc

CME CREDIT INFORMATION

Release Date: 05/15/08

Expiration Date: 05/14/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount data from clinical studies of the use of the integrase inhibitors raltegravir and elvitegravir
Discuss the role of integrase inhibitors in the management of treatment-experienced patients
Identify management strategies for antiretroviral-experienced patients who experience virologic failure

Topics covered include:

Introduction
Optimal Management of Virologic Failure in Multiclass-Experienced Patients
Pharmacology of Current Integrase Inhibitors: Implications for Dosing and Interactions
Use of Integrase Inhibitors in Treatment-Experienced Patients With Virologic Failure
Use of Integrase Inhibitors in Treatment-Experienced Patients With Virologic Suppression
Use of Integrase Inhibitors in Treatment-Naive Patients
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.